



Afinitor Disperz® (everolimus) – First-time generic

- On October 1, 2021, Mylan/Viatris launched an [AB-rated](#) generic version of Novartis' [Afinitor Disperz \(everolimus\)](#) tablet for oral suspension.
- Afinitor Disperz is approved for the treatment of tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated partial-onset seizures.
- Everolimus is also available generically as 2.5 mg, 5 mg, 7.5 mg and 10 mg tablets (Afinitor®) and 0.25 mg, 0.5 mg, 0.75 mg and 1 mg tablets ([Zortress®](#)).
 - Afinitor is approved to treat hormone receptor-positive, HER2-negative breast cancer, neuroendocrine tumors, renal cell carcinoma, TSC-associated renal angiomyolipoma and TSC-associated SEGA.
 - Zortress is approved for the prophylaxis of organ rejection in kidney and liver transplantation.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.